---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004666"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-09-30T12:52:08+00:00"
generated_at: "2026-10-12T13:59:17.129684+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Silexion doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer

## Summary
- First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov) in Israel on September 30, 2026, Silexion announced.
- Phase 2/3 trial evaluates SIL204 plus standard chemotherapy versus chemotherapy alone in unresectable Stage 3 LAPC with confirmed KRAS mutation.
- Trial starts with a safety run-in of about 18 patients, then expands to a randomized cohort of about 166 patients.
- SIL204 uses EUS-guided intratumoral delivery plus subcutaneous abdominal injections; additional Israel and Germany sites are expected to join.
- CEO Ilan Hadar called the dosing a defining operational and clinical milestone for Silexion's lead RNAi program.

## SEC filing metadata
- accession: 0001178913-26-004666
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-09-30T12:52:08+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/0001178913-26-004666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004666/zk2636171.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004666
- JSON: https://secwatch.observer/filing/0001178913-26-004666.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004666.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.